Indeed, the median survival of 3q-rearranged AML patients is only 10 months.32EVI1 is overexpressed in around 10%–28% of pediatric AML cases, where it predicts a poor prognosis and is associated with MLL rearrangements in around one-third of the cases, while 3q rearrangements are very rare.29,33. The gene discussed is KMT2A; the disease is acute myeloid leukemia.